Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance.
Christopher A DarlowNicola FarringtonAdam JohnsonLaura McEnteeJennifer UnsworthAna Jimenez-ValverdeRuwanthi Kolamunnage-DonaRenata M A Da CostaSally EllisFrançois FranceschiMike SharlandMichael NeelyLaura J V PiddockShampa DasWilliam HopePublished in: The Journal of antimicrobial chemotherapy (2022)
These data suggest that flomoxef/fosfomycin could be an efficacious and synergistic regimen for the empirical treatment of neonatal sepsis in LMIC settings with prevalent antimicrobial resistance. Our HFIM results warrant further assessment of the flomoxef/fosfomycin combination in clinical trials.